BioMérieux: targets set for 2024-28
The group also aims to increase its operating profit from ordinary activities to 20% of sales in 2028, at constant exchange rates and scope of consolidation (compared with 16.5% in 2023), with annual organic growth of at least 10% per annum until 2028.
Finally, the in vitro diagnostics specialist forecasts annual capital expenditure of between 8% and 10% of sales over the 2025-28 period, as well as a dividend payout ratio of around 25% of net income, group share.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction